| Business Summary | | Novavax,
Inc.
is
a
specialty
biopharmaceutical
company
engaged
in
the
research,
development
and
commercialization
of
proprietary
products
focused
on
women's
health
and
infectious
diseases.
The
Company's
product
development
efforts
are
focused
on
the
research
and
development
of
proprietary
drug
delivery
and
vaccine
technologies
and
the
applications
of
those
technologies.
Its
technology
platforms
involve
the
use
of
proprietary,
microscopic,
organized,
non-phospholipid
structures
as
vehicles
for
the
delivery
of
a
wide
variety
of
drugs
and
other
therapeutic
products,
including
certain
hormones,
anti-bacterial
and
anti-viral
products
and
vaccine
adjuvants.
In
addition,
the
Company
is
engaged
in
contract
research
and
development
and
Phase
I
and
Phase
II
vaccine-manufacturing
of
human
vaccines
for
its
own
use,
for
government
laboratories
and
for
other
vaccine
companies. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Novavax,
Inc.
is
a
biopharmaceutical
company
that
researches
and
develops
drug
products
for
women's
health,
infectious
diseases
and
cancer.
For
the
six
months
ended
6/30/01,
revenues
totaled
$12.9
million
up
from
$1.3
million.
Net
loss
increased
1%
to
$4
million.
Revenues
benefitted
from
the
12/00
acquisition
of
Fielding
Pharmaceutical
Company.
Higher
losses
reflect
increased
acquisition
related
sales
and
market
expenses
and
higher
debt
levels. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Denis O'Donnell, M.D., 47 Chairman | $125K | John Spears, 51 Pres,
CEO, Director | 453K | Dennis Genge, 48 CFO,
VP, Treasurer | -- | James Mirto, 58 Sr.
VP, COO | 131K | D.Craig Wright, M.D., 50 CSO | 229K | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|